This book introduces charnolophagy (CP) as energy-driven, lysosomal-dependent mitochondrial inclusion-specific pleomorphic Charnoly body (CB) autophagy (ATG) involving free radical-induced Ca2+ dyshomeostasis, ΔΨ collapse, and ATP depletion in congenital diseases, pressure ulcers, metabolic diseases, hepatic diseases, diabetes, obesity, inflammatory diseases, musculoskeletal diseases, sarcopenia, cachexia, respiratory diseases, gastrointestinal diseases, hyperlipidemia, skin and hair diseases, pulmonary diseases, cardiovascular diseases, renal diseases, sepsis-induced multi-organ failure, reproductive diseases, inflammatory diseases, ophthalmic diseases, neurodegenerative diseases, drug addiction, aging, microbial (including COVID-19) infections, and belligerent malignancies implicated in early morbidity and mortality and disease-specific spatiotemporal, targeted, safe, and effective evidence-based personalized theranostic charnolopharmacotherapeutics to cure them. Basic DRESS and GELS principles, nanoparticles to cure chronic multidrug-resistant (MDR) diseases, antioxidants as free radical scavengers, CB antagonists, CP regulators, and CS stabilizers to curb CB molecular pathogenesis (CBMP) are described for better quality of life and longevity. Specific guidelines for environmental protection and preservation of zoological and botanical species at the verge of extinction, Triple "I" Hypothesis for mitochondrial quality control, and transcriptional regulation of CSexR and CSendoR to cure chronic diseases are presented. Novel CP index is introduced to evaluate MDR malignancies and other chronic diseases. WHO, CDC, FDA, NIH, policy planners, cosmetologists, trichologists, players, athletes, dancers, wrestlers, equestrians, young women, aging population, toxicologists, environmental protectionists, pharmaceutical industry, biomedical scientists, researchers, medical students, physicians, nurses, paramedical professionals, and global audience will be interested in this
...
閱讀全文
